Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Non-Diabetic Cardiac Remodeling (EMPA-HEART 2)
NCT04461041Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- Apr 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of empagliflozin in left ventricular hypertrophy (LVH), sponsored by Unity Health Toronto. Started Apr 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT04461041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04461041.